Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Gynecology

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 24 articles: HTML format

Single Articles

July 2025
1. DOGRA S, Elayapillai SP, Qu D, Pitts K, et al
   Corrigendum to "Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer" [Cancer Lett. 2023 Dec 1;578:216437].
   Cancer Lett. 2025 Jul 2:217889. doi: 10.1016/j.canlet.2025.217889.
   PubMed    
   
   
   June 2025
2. AO K, Yin M, Lyu X, Xiao Y, et al
   Corrigendum to "METTL3-mediated HSPA9 m6A modification promotes malignant transformation and inhibits cellular senescence by regulating exosomal mortalin protein in cervical cancer" [Cancer Lett. 587 (2024) 216658].
   Cancer Lett. 2025 Jun 3:217827. doi: 10.1016/j.canlet.2025.217827.
   PubMed    
   
   
   May 2025
3. GONG Y, Zhang W, Wang X, Zheng S, et al
   A previously uncharacterized role of TAp73 in ferroptosis by modulating oxidative homeostasis in cervical cancer.
   Cancer Lett. 2025;627:217815.
   PubMed     Abstract available
   
   
   April 2025
4. DURAKI D, Jabeen M, Mao C, Wang L, et al
   A Necrosis Inducer Promotes an Immunogenic Response and Destroys Ovarian Cancers in Mouse Xenografts and Patient Ascites Organoids.
   Cancer Lett. 2025 Apr 29:217738. doi: 10.1016/j.canlet.2025.217738.
   PubMed     Abstract available
   
   
   March 2025
5. LI H, Chatla S, Liu X, Tian Z, et al
   ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination.
   Cancer Lett. 2025;613:217505.
   PubMed     Abstract available
   
   
   February 2025
6. WANG Q, Liu W, Fan Y, Liu S, et al
   Enhancing the Antitumor Effect of MUC16 CART Cells in Ovarian Cancer: The Potential of Oncolytic Adenovirus.
   Cancer Lett. 2025 Feb 25:217588. doi: 10.1016/j.canlet.2025.217588.
   PubMed    
   
   
   
7. TAMURA T, Nagai S, Masuda K, Imaeda K, et al
   mTOR-mediated p62/SQSTM1 stabilization confers a robust survival mechanism for ovarian cancer.
   Cancer Lett. 2025 Feb 17:217565. doi: 10.1016/j.canlet.2025.217565.
   PubMed     Abstract available
   
   
   
8. GUO M, He M, Dang Y, Lei L, et al
   Predictors of para-aortic lymph node metastasis based on pathological diagnosis via surgical staging in patients with locally advanced cervical cancer: A multicenter study.
   Cancer Lett. 2025 Feb 15:217545. doi: 10.1016/j.canlet.2025.217545.
   PubMed     Abstract available
   
   
   
9. LI X, Yang X, Lin S, Cong H, et al
   Perineural Invasion in Cervical Cancer.
   Cancer Lett. 2025 Feb 14:217561. doi: 10.1016/j.canlet.2025.217561.
   PubMed     Abstract available
   
   
   December 2024
10. LOMELI N, Pearre DC, Lepe J, Argueta DA, et al
    N-acetylcysteine prevents cisplatin-induced cognitive impairments in an ovarian cancer rat model.
    Cancer Lett. 2024 Dec 18:217405. doi: 10.1016/j.canlet.2024.217405.
    PubMed     Abstract available
    
    
    November 2024
11. FIELD NR, Dickson KA, Nassif NT, Marsh DJ, et al
    SMARCA4 and SMARCA2 co-deficiency: An uncommon molecular signature defining a subset of rare, aggressive and undifferentiated malignancies associated with defective chromatin remodeling.
    Cancer Lett. 2024;605:217282.
    PubMed     Abstract available
    
    
    
12. BHOWMIK AD, Shaw P, Gopinatha Pillai MS, Rao G, et al
    Evolving Landscape of Detection and Targeting miRNA/Epigenetics for Therapeutic Strategies in Ovarian Cancer.
    Cancer Lett. 2024 Nov 28:217357. doi: 10.1016/j.canlet.2024.217357.
    PubMed     Abstract available
    
    
    October 2024
13. NING Y, Chen Y, Tian T, Gao X, et al
    S100A7 Orchestrates Neutrophil Chemotaxis and Drives Neutrophil Extracellular Traps (NETs) Formation to Facilitate Lymph Node Metastasis in Cervical Cancer Patients.
    Cancer Lett. 2024 Oct 7:217288. doi: 10.1016/j.canlet.2024.217288.
    PubMed     Abstract available
    
    
    September 2024
14. LEWIS F, Beirne J, Henderson B, Norris L, et al
    Unravelling the biological and clinical challenges of circulating tumour cells in epithelial ovarian carcinoma.
    Cancer Lett. 2024 Sep 26:217279. doi: 10.1016/j.canlet.2024.217279.
    PubMed     Abstract available
    
    
    August 2024
15. WU H, Sun C, Cao W, Teng Q, et al
    Blockade of the lncRNA-PART1-PHB2 axis confers resistance to PARP inhibitor and promotes cellular senescence in ovarian cancer.
    Cancer Lett. 2024;602:217192.
    PubMed     Abstract available
    
    
    July 2024
16. JAISWAL SK, Fedkenheuer K, Khamar R, Tan H, et al
    The Megacomplex protects ER-alpha from degradation by Fulvestrant in epithelial ovarian cancer.
    Cancer Lett. 2024 Jul 22:217129. doi: 10.1016/j.canlet.2024.217129.
    PubMed     Abstract available
    
    
    
17. XU J, Lu W, Wei X, Zhang B, et al
    Single-cell transcriptomics reveals the aggressive landscape of high-grade serous carcinoma and therapeutic targets in tumor microenvironment.
    Cancer Lett. 2024;593:216928.
    PubMed     Abstract available
    
    
    June 2024
18. FENG X, Ji Z, Fan X, Kong Y, et al
    ASS1 Enhances Anoikis Resistance via AMPK/CPT1A-mediated Fatty Acid Metabolism in Ovarian Cancer.
    Cancer Lett. 2024 Jun 22:217082. doi: 10.1016/j.canlet.2024.217082.
    PubMed     Abstract available
    
    
    
19. MENG H, Miao H, Zhang Y, Chen T, et al
    YBX1 promotes homologous recombination and resistance to platinum-induced stress in ovarian cancer by recognizing m5C modification.
    Cancer Lett. 2024 Jun 14:217064. doi: 10.1016/j.canlet.2024.217064.
    PubMed     Abstract available
    
    
    
20. YU Y, Lyu C, Li X, Yang L, et al
    Remodeling of tumor microenvironment by extracellular matrix protein 1a differentially regulates ovarian cancer metastasis.
    Cancer Lett. 2024;596:217022.
    PubMed     Abstract available
    
    
    April 2024
21. HA JH, Radhakrishnan R, Nadhan R, Gomathinayagam R, et al
    Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Target in Ovarian Cancer.
    Cancer Lett. 2024 Apr 18:216891. doi: 10.1016/j.canlet.2024.216891.
    PubMed     Abstract available
    
    
    
22. KAUR P, Shankar E, Gupta S
    EZH2-mediated development of therapeutic resistance in cancer.
    Cancer Lett. 2024;586:216706.
    PubMed     Abstract available
    
    
    March 2024
23. PONGRATANAKUL P, Bremmer F, Pauls S, Poschmann G, et al
    Assessing the risk to develop a growing teratoma syndrome based on molecular and epigenetic subtyping as well as novel secreted biomarkers.
    Cancer Lett. 2024;585:216673.
    PubMed     Abstract available
    
    
    
24. CAO C, Xu Q, Zhu Z, Xu M, et al
    Three-dimensional chromatin analysis reveals Sp1 as a mediator to program and reprogram HPV-host epigenetic architecture in cervical cancer.
    Cancer Lett. 2024 Mar 10:216809. doi: 10.1016/j.canlet.2024.216809.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.